CardioGenesis raises $6m for minimally invasive products:
This article was originally published in Clinica
CardioGenesis, which makes surgical products and accessories for transmyocardial revascularisation (TMR) and percutaneous myocardial channelling (PMC) procedures, has raised $6m from Laurus Funds. It plans to use the proceeds to introduce new minimally invasive TMR products and fund further R&D. The company also wants to obtain FDA approval for its PMC technology. Chairman, president and CEO Michael Quinn said the minimally invasive tools should help expand the number of angina patients treated with TMR. To date about 30,000 patients have been treated.